Category: Ozempic
-
No-Shows, Ozempic, and the £50 Fee: Restaurants Have Had Enough
•
It is not exactly the end of civilization, but I love anger a little when it comes to modern food habits. These days, even if you suggest that a restaurant may have to protect itself from the lack of borders, expect a torrent of discontent. However, we are here, with…
-
Ozempic may help manage opioid addiction: study
•
People with a history of opioid abuse who took Novo Nordisk A/S’s Ozempic were less likely to overdose, a study has shown, adding to a growing body of evidence that it may help manage addiction. Patients taking semaglutide, the main ingredient in Novo’s diabetes drug Ozempic, and the weight-loss injection…
-
Could Ozempic increase suicidal thoughts?
•
Medications such as Ozempic and wegovy — also known as glucagon-like peptide-1 (GLP-1) or semaglutide medications — have been linked to increased suicidal thoughts, he says. A new study published in JAMA Open Network On August 20th. “The detected signal of suicidal thoughts associated with semaglutide deserves urgent clarification,” the…
-
Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy By Reuters
•
(Reuters) – Novo Nordisk (NYSE:) CEO Lars Jorgensen has agreed to voluntarily testify at a hearing focusing on U.S. prices for weight-loss drugs Ozempic and Wegovy, the Senate Committee on Health, Education, Labor and Pensions said on Friday. A vote by the US Senate Health Committee, which was scheduled to…
-
US Senate panel to weigh Novo Nordisk subpoena over Ozempic, Wegovy prices By Reuters
•
WASHINGTON (Reuters) – The U.S. Senate Health Committee said on Tuesday it will vote this month on whether to subpoena Novo Nordisk (NYSE:) to answer questions about U.S. prices for weight-loss drugs Ozempic and Wegovy, which are much higher than their prices in other countries. . countries. The Senate Committee…
-
Hims 85% Wegovy and Ozempic discount is latest step on a journey to make medicine less ‘paternalistic,’ exec says
•
Traditional medical practices are getting a boost from new entrants seeking to fill gaps in what health industry executives described Monday as an underdeveloped health care system. That includes Hims & Hers, a direct-to-consumer health company that announced Monday that it will launch a combination version of its weight-loss drugs…